The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

The agency changed course just days after firing employees who oversee the safety of food and life-sustaining medical devices ...

Staff units evaluating high-tech surgical robots and insulin-delivery systems were gutted by Trump layoffs even though ...

“Our internal and external experts all believe that the implementational time frame, while not as fast as we had hoped, are ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

Mariposa California's original daily updated online newspaper is the premier site for news and information on Yosemite, ...